Search

Displaying results 3391 - 3400 of 9322 in total
  1. Drug

    Rentiapril

    go.drugbank.com/drugs/DB20567
    Experimental

    The usage of the INN stem '-pril' in the name indicates that Rentiapril is a angiotensin-converting enzyme inhibitor. Rentiapril has a monoisotopic molecular weight of 313.04 Da.

    Categories: Agents Acting on the Renin-Angiotensin System
  2. Drug

    Nesiritide

    go.drugbank.com/drugs/DB04899
    ApprovedInvestigationalWithdrawn

    Nesiritide is a medication used to treat acutely decompensated congestive heart failure with dyspnea at rest or with minimal exertion (such as talk, eating or bathing).

  3. Drug

    Oxyphenbutazone

    go.drugbank.com/drugs/DB03585
    ApprovedWithdrawn

    Oxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.

  4. Drug

    Obecabtagene autoleucel

    go.drugbank.com/drugs/DB17362
    ApprovedInvestigational

    [A265050] On November 8, 2024, obecabtagene autoleucel was approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia. … Obecabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy with a fast off-rate binding profile for CD19.

    Categories: Genetically-modified Autologous T Cells, CD19-Directed Genetically Modified Autologous T-cell ImmunotherapiesSynonyms: SELF-INACTIVATING LENTIVIRAL VECTOR CONSISTING OF 5' FUSION BETWEEN THE CMV PROMOTER AND HIV LTR, WHERE THE CMV PROMOTER REPLACES THE U3 REGION., PACKAGING SIGNAL (.PSI.), THE REV RESPONSIVE ELEMENT (RRE) AND THE CENTRAL POLYPURINE TRACT (CPPT) ARE RETAIN
  5. Drug

    Tildrakizumab

    go.drugbank.com/drugs/DB14004
    ApprovedInvestigational

    The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy … A study was performed on the pharmacokinetics of this drug on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects [A32257].

  6. Drug

    Paricalcitol

    go.drugbank.com/drugs/DB00910
    ApprovedInvestigational

    Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.

  7. Drug

    Poa pratensis pollen

    go.drugbank.com/drugs/DB10366
    Approved

    Poa pratensis pollen is the pollen of the Poa pratensis plant. Poa pratensis pollen is mainly used in allergenic testing.

    Mixtures: K-O-T Standardized Grass Pollen Mix, K-O-T Standardized Grass Pollen Mix
  8. Drug

    Trichloroethylene

    go.drugbank.com/drugs/DB13323
    Approved

    Trichloroethylene is a halocarbon commonly used as an industrial solvent, not to be confused with the similar 1,1,1-trichloroethane, also known as chlorothene. … Environmental exposure, particularly groundwater and drinking water contamination from industrial discharge, is a major concern for human health and has been the subject of numerous incidents and lawsuits

    Synonyms: TCE
  9. Drug

    Ethoheptazine

    go.drugbank.com/drugs/DB08988
    ApprovedWithdrawn

    Ethoheptazine is marketed under the name Zactane. It is a phenazepine based opioid analgesic. It was invented in the 1950s and is related to other drugs such as proheptazine. … Ethoheptazine is no longer marketed in the United States.

  10. Drug

    Levopropoxyphene

    go.drugbank.com/drugs/DB06793
    ApprovedWithdrawn

    Levopropoxyphene is a stereoisomer of propoxyphene in the form of 2S, 3R enantiomer. It was sold as an antitussive, but it was removed from the market in the 70s.